Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells

Vaccine

Volumn 32, Issue 26, 2014, Pages 3285-3292

  Mishra, Sasmita ^a   Losikoff, Phyllis T ^a   Self, Alyssa A ^a   Terry, Frances ^b   Ardito, Matthew T ^b   Tassone, Ryan ^b   Martin, William D ^b   De Groot, Anne S ^b,c   Gregory, Stephen H ^a  

^a BROWN UNIVERSITY   (United States)

^b EpiVax Inc   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Dendritic cell; EpiMatrix; Epitope; HCV; T cell; Vaccine

Indexed keywords

DNA; EPITOPE; GAMMA INTERFERON; HEPATITIS C VACCINE; HEPATITIS C VIRAL EPITOPE; HLA A2 ANTIGEN; HLA DRB1 ANTIGEN; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BIOINFORMATICS; BLOOD DONOR; CELL POPULATION; COCULTURE; CONSENSUS SEQUENCE; DENDRITIC CELL; EX VIVO STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENICITY; PEPTIDE PULSED DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

DENDRITIC CELL; EPIMATRIX; EPITOPE; HCV; T CELL; VACCINE;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; DENDRITIC CELLS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HEPACIVIRUS; HLA-A2 ANTIGEN; HLA-DRB1 CHAINS; HUMANS; INTERFERON-GAMMA; PEPTIDES; T-LYMPHOCYTES; VIRAL HEPATITIS VACCINES;

EID: 84900430398     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.083     Document Type: Article

References (45)

1. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5(6):453-463.
2. Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993, 67(3):1385-1395.
3. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996, 98(3):706-714.
4. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191(9):1499-1512.
5. El Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36(5 Suppl 1):S74-S83.
6. Schaefer E.A., Chung R.T. Anti-hepatitis C virus drugs in development. Gastroenterology 2012, 142(6):1340-1350.
7. U.S.Food and Drug Administration Incivek (telaprevir) in combination with drugs peginterferon alfa and ribavirin (incivek combination treatment): drug safety communication-serious skin reactions 2012, Electronic Communication, USDA Website.
8. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85(Pt 11):3173-3188.
9. Yu C.I., Chiang B.L. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010, 2010:548280.
10. Halliday J., Klenerman P., Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011, 10(5):659-672.
11. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
12. Encke J., Findeklee J., Geib J., Pfaff E., Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 2005, 142(2):362-369.
13. Kuzushita N., Gregory S.H., Monti N.A., Carlson R., Gehring S., Wands J.R. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology 2006, 130(2):453-464.
14. Weigand K., Voigt F., Encke J., Hoyler B., Stremmel W., Eisenbach C. Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice. World J Gastroenterol 2012, 18(8):785-793.
15. Gowans E.J., Roberts S., Jones K., Dinatale I., Latour P.A., Chua B., et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010, 53(4):599-607.
16. Kuiken C., Yusim K., Boykin L., Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005, 21(3):379-384.
17. Yusim K., Richardson R., Tao N., Dalwani A., Agrawal A., Szinger J., et al. Los Alamos hepatitis C immunology database. Appl Bioinf 2005, 4(4):217-225.
18. Schafer J.R., Jesdale B.M., George J.A., Kouttab N.M., De Groot A.S. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 1998, 16(19):1880-1884.
19. Ellis J.M., Henson V., Slack R., Ng J., Hartzman R.J., Katovich H.C. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum Immunol 2000, 61(3):334-340.
20. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998, 160(7):3363-3373.
21. De Groot A.S., Jesdale B.M., Szu E., Schafer J.R., Chicz R.M., Deocampo G. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retroviruses 1997, 13(7):529-531.
22. De Groot A.S., Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009, 131(2):189-201.
23. De Groot A.S., Bishop E.A., Khan B., Lally M., Marcon L., Franco J., et al. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods 2004, 34(4):476-487.
24. Ardito M., Fueyo J., Tassone R., Terry F., DaSilva K., Zhang S., et al. An integrated genomic and immunoinformatic approach to H. pylori vaccine design. Immunome Res 2011, 7(2):1.
25. McMurry J.A., Gregory S.H., Moise L., Rivera D., Buus S., De Groot A.S. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 2007, 25(16):3179-3191.
26. Buchli R., VanGundy R.S., Hickman-Miller H.D., Giberson C.F., Bardet W., Hildebrand W.H. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201-a new tool for epitope discovery. Biochemistry 2005, 44(37):12491-12507.
27. Meyer T.P., Zehnter I., Hofmann B., Zaisserer J., Burkhart J., Rapp S., et al. Filter Buffy Coats (FBC): a source of peripheral blood leukocytes recovered from leukocyte depletion filters. J Immunol Methods 2005, 307(1-2):150-166.
28. Wullner D., Zhou L., Bramhall E., Kuck A., Goletz T.J., Swanson S., et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 2010, 137(1):5-14.
29. + T cells. J Immunol Methods 2010, 353(1-2):8-19.
30. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):1433-1444.
31. Tungol A., Rademacher K., Schafer J.A. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm 2011, 17(9):685-694.
32. Department of Health and Human Services Combating the silent epidemic of viral hepatitis: action plan for the prevention, care & treatment of viral hepatitis 2011, Department of Health and Human Services, http://www.hhs.gov/ash/initiatives/hepatitis/actionplan_viralhepatitis2011.pdf.
33. Lauer G.M. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013, 207(Suppl 1):S7-S12.
34. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134(5):1385-1395.
35. Yutani S., Yamada A., Yoshida K., Takao Y., Tamura M., Komatsu N., et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007, 25(42):7429-7435.
36. Weiland O., Ahlen G., Diepolder H., Jung M.C., Levander S., Fons M., et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther 2013, 21:1796-1805.
37. Habersetzer F., Honnet G., Bain C., Maynard-Muet M., Leroy V., Zarski J.P., et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011, 141(3):890-899.
38. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12(4):265-277.
39. Boonstra A., van der Laan L.J., Vanwolleghem T., Janssen H.L. Experimental models for hepatitis C viral infection. Hepatology 2009, 50(5):1646-1655.
40. Levitz L., Koita O.A., Sangare K., Ardito M.T., Boyle C.M., Rozehnal J., et al. Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine 2012, 30(52):7547-7560.
41. Selin L.K., Wlodarczyk M.F., Kraft A.R., Nie S., Kenney L.L., Puzone R., et al. Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity 2011, 44(4):328-347.
42. Sharma S., Thomas P.G. The two faces of heterologous immunity: protection or immunopathology. J Leukoc Biol 2014, 95(4):405-416.
43. Metz P., Dazert E., Ruggieri A., Mazur J., Kaderali L., Kaul A., et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 2012, 56(6):2082-2093.
44. + T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 2009, 136(4):1391-1401.
45. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50(3-4):201-212.